Meeting the Bottleneck Challenge

Many industry commentators have highlighted the current worldwide shortage of manufacturing facilities for monoclonal antibodies and other recombinant proteins. An estimate, using the number of non-monoclonal antibodies biopharmaceuticals currently in the pipeline, that in the next 3-5 years, manufacturing capacity will fall short by 2-3 times what is required. The shortfall is even more severe for monoclonal antibodies where the requirement is likely to be 5-6 times current capacities. There is a critical need for increased manufacturing capacity or many of these potential new and life saving biological drugs will be significantly delayed. Cost to build a manufacturing facility and other issues are causing a shift from in-house manufacturing to outsourcing with contract manufacturing facilities.

We provide personalized contract manufacturing services to biotechnology and biopharmaceutical companies engaged in pre-clinical through commercial manufacturing. The major benefits of using Avid Bioservices for your contract manufacturing needs are:

Our mammalian cell bioprocessing facility has been licensed by the state of California specifically for the manufacture of biological products.
Our extensive experience utilizing stirred tank bioreactors coupled with our abilities to source and screen cell culture formulations from various suppliers are at your disposal to assist in achieving optimum performance for your application.
Using us will reduce your initial start-up cost by eliminating the need to build your own cGMP facility.

The main advantage of using mammalian cell cultures for the manufacturing of biopharmaceuticals such as proteins and antibodies as opposed to competing technologies such as bacteria or yeast is that mammalian cell cultures such as murine hybridoma, NS0 and Chinese Hamster Ovary (CHO) are capable of expressing proteins with glycosylation patterns similar or identical to those found in humans.